Intech Investment Management LLC Buys 11,174 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Intech Investment Management LLC lifted its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 86.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 24,113 shares of the life sciences company's stock after acquiring an additional 11,174 shares during the quarter. Intech Investment Management LLC's holdings in Integra LifeSciences were worth $547,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. Nisa Investment Advisors LLC boosted its stake in Integra LifeSciences by 599.6% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after acquiring an additional 2,800 shares during the last quarter. Empowered Funds LLC purchased a new position in Integra LifeSciences in the fourth quarter valued at approximately $180,000. Centiva Capital LP bought a new position in Integra LifeSciences during the third quarter valued at $192,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences in the third quarter valued at $198,000. Finally, Romano Brothers AND Company bought a new stake in shares of Integra LifeSciences in the fourth quarter valued at $204,000. 84.78% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Morgan Stanley began coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 price objective for the company. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of "Hold" and an average target price of $23.00.

Remove Ads

Integra LifeSciences Price Performance

IART traded down $0.32 during trading on Friday, reaching $21.69. 463,964 shares of the company were exchanged, compared to its average volume of 1,047,311. Integra LifeSciences Holdings Co. has a 12-month low of $16.81 and a 12-month high of $35.49. The company's 50-day moving average is $23.83 and its two-hundred day moving average is $22.12. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The company has a market cap of $1.67 billion, a price-to-earnings ratio of -240.97, a P/E/G ratio of 0.73 and a beta of 1.23.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.85 by $0.12. The firm had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company's revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.89 earnings per share. Research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.